Pharmasset target raised to $27 from $18 at Leerink
Leerink raised its valuation for Pharmasset after channel checks indicated RG7128's Phase IIb trial is progressing well. The firm keeps an Outperform rating on the stock. :theflyonthewall.com
News For VRUS From The Last 14 Days
Check below for free stories on VRUS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
